ReviewFrontiers in cellular and infection microbiology2025
Respiratory diseases and the gut microbiota: an updated review.
Review in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global research status and development trends of chronic obstructive pulmonary disease and gut microbiota: a comprehensive analysis based on bibliometrics and knowledge visualization.Frontiers in microbiology · 2026Pooled it
- Gut microbiota-immune-metabolic crosstalk in acute lung injury: integrating the gut-lung axis from mechanism to therapeutic targeting.Seminars in immunopathology · 2026Review
- The Impact of Plant-Derived Foods and Medicines on the Lung-Gut Axis and Microbiota Cross-Talk.Molecules (Basel, Switzerland) · 2026Review
- Prognostic value of gut microbiota-derived metabolites in non-small cell lung cancer: a retrospective cohort study of overall survival.Translational cancer research · 2026Article
- Distinct Basal Gut Microbiota Profiles Are Associated with Strain-Specific Lung Responses toBiology · 2026Article
- Effects of an herbal extract mixture (Veterinary and animal science · 2026Article
- Review
- The Airway Microbiome as a Modulator of Influenza Virus Infection: Mechanistic Insights and Translational Perspectives-Review.Pathogens (Basel, Switzerland) · 2026Review
- The neonatal lung microbiome: a dynamic determinant of respiratory health, disease, and novel therapeutics.Frontiers in pediatrics · 2026Review
- Preoperative gut microbiota depletion and metabolomic signatures predict postoperative pneumonia in patients with intracranial space-occupying lesions: a multi-omics prospective cohort study.Frontiers in immunology · 2026Article
- Microbiome stewardship: definition and guiding principles for implementation.Sustainable microbiology · 2026Article
- Helminth Infection, Gut Microbiome Alterations, and Their Impact on Pulmonary Tuberculosis Susceptibility.Journal of tropical medicine · 2026Review
- Review
- Dual role of IL-17A in COPD: amplifier of inflammatory cascades and mediator of airway remodeling and alveolar destruction.Frontiers in immunology · 2026Review
- The gut-lung axis in COPD: immunomodulatory roles of gut microbiota and novel therapeutic strategies.Frontiers in immunology · 2026Review
- Exploring microbial signatures in sarcoidosis: etiological and therapeutic implications of host-microbiota interactions.Frontiers in immunology · 2026Review
- Research Advances on the Impact of Gut Microbiota on COPD: Exploring New Perspectives on the Microbiota-Gut-Lung Axis.Current microbiology · 2025Review
- Qingfei Dayuan granules and decoction alleviate acute lung injury via TLR4 signaling pathway modulation, gut microbiota regulation, and metabolic reprogramming.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gut microbiota constitutes a vital ecosystem within the human body playing a pivotal role in immune regulation and metabolic homeostasis. Emerging research underscores a sophisticated interplay between the gut and lungs, termed the "gut-lung axis." Gut microbes exert influence over pulmonary immunity and metabolism via immune mediators (e.g., cytokines and interleukins), metabolites (e.g., short-chain fatty acids) and direct microbial translocation. Dysbiosis of the gut microbiota has been implicated in a spectrum of respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), acute lung injury (ALI), Coronavirus Disease 2019 (COVID-19), lung cancer, idiopathic pulmonary fibrosis (IPF), pulmonary arterial hypertension (PAH), acute lower respiratory infection (ALRI) and tuberculosis (TB). Although multi-omics technologies have elucidated certain mechanisms underlying the gut-lung axis, numerous pathways remain to be fully delineated. This review synthesizes current knowledge on the role of gut microbiota and their metabolites in respiratory diseases and assesses their therapeutic potential. Future investigations should prioritize strategies to restore and maintain microbial homeostasis, such as dietary modifications, probiotic supplementation and fecal microbiota transplantation to pioneer novel preventive and therapeutic approaches. These summaries of advances in gut microbiology research promise better management and exploration of therapeutic strategies for respiratory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.